The enzyme α-methylacyl CoA racemase (AMACR) is involved in the metabolism of branched-chain fatty acids and has been identified as a promising therapeutic target for prostate cancer. By using the recently available human AMACR from HEK293 kidney cell cultures, we tested a series of new rationally designed inhibitors to determine the structural requirements in the acyl component. An N-methylthiocarbamate (Ki=98 nM), designed to mimic the proposed enzyme-bound enolate, was found to be the most potent AMACR inhibitor reported to date.
Keywords: AMACR; MCR; coenzyme A; inhibitors; α‐methylacyl CoA racemase.
Copyright © 2013 WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim.